Meta AnalysisID 7592
双氢青蒿素-哌喹用于非洲五岁以下儿童疟疾化学预防的安全性：一项系统评价
CRD42023451008
How safe is Dihydroartemisinin-Piperaquine when used for malaria chemoprevention in under-five and school-going children in Sub-Saharan Africa
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7592
- Evidence Id
- 16150
- Core Evidence Id
- 16150
- Source Meta Analysis Id
- 7584
- Herb2 Meta Analysis Id
- HBMA007584
- Crd Id
- CRD42023451008
- Title
- A systematic review of the safety of Dihydroartemisinin-piperaquine used for malaria chemoprevention in under-five children in Africa
- Review Question
- How safe is Dihydroartemisinin-Piperaquine when used for malaria chemoprevention in under-five and school-going children in Sub-Saharan Africa
- Study Type Included
- We will include randomized trials and cohort studies to assess the safety of Dihydroartemisinin-piperaquine used for malaria chemoprevention in under-five and school going children in Africa.
- Condition Being Studied
- Severe Malaria; Cause of morbidity and mortality in under-five and school going children, in Africa
- Participant
- Under-five and school-going children receiving malaria chemo-prevention with Dihydroartemisinin-piperaquine as an intervention Middle adolescents (16-17 years) and older age group (above 18 years).
- Animal
- Human Disease Modelled
- Intervention
- Under-five and school going children who are at risk of developing severe malaria and are receiving Dihydroartemisinin-piperaquine as an intervention for malaria prevention in Africa.
- Comparator Control
- The control group of under-five and school going children receiving placebo or another approved antimalarial e.g Sulphadoxine-Pyrimethamine (SP), Chloroquine, Lumefantrine artemether, amodiaquine and cotrimoxazole administered for malaria chemoprevention in different African countries.
- Main Outcome
- 1. Signs of cardiotoxicity: A child presenting with shortness of breath, severe chest pains, heart palpitations, dizziness, abdominal distension, and swelling of the legs. Can also be measured through ECG monitoring showing prolonged QTc interval (QTc interval of > 440 ms in children 1–15 years of age. 2. Serious adverse drug reactions: Any response to Dihydroartemisinin-piperaquine which is noxious and unintended, and which occurred at doses normally used in man for malaria treatment or prophylaxis. These include life-threatening event or reaction that results in death, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity, or substantial disruption of the ability to conduct normal life functions. Measures of effect Individual study data will be obtained and analyze the pooled cardiotoxicity data by calculating measures of effect (risk/rate ratios, Relative Risk, Risk Difference, and Confidence intervals from individual studies to ascertain the safety of Dihydroartemisinin piperaquine for malaria chemoprevention. The overall measure of effect will be calculated as a weighted average of the individual summary statistics to provide statistical significance.
- Outcome Measure
- Additional Outcome
- None Measures of effect None
- Study Method
- Systematic review
- Keyword
- Chemoprevention; Child; Humans; Malaria; Schools; artenimol; piperaquine
- Contact
- Chimwemwe Kana [email protected]
- Organisational Affiliation
- Training and Research Unit of Excellency https://true.mw/
- Funding Source
- This work will be supported by the Training and Research Unit of Excellence, Malawi
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Malawi
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-08-07
- Registration Date
- 2023-08-17
- Anticipated Start Date
- 2023-09-01
- Anticipated Completion Date
- 2024-01-31
- Title Cn
- 双氢青蒿素-哌喹用于非洲五岁以下儿童疟疾化学预防的安全性：一项系统评价
- Title En
- A systematic review of the safety of Dihydroartemisinin-piperaquine used for malaria chemoprevention in under-five children in Africa
- Bilingual Status
- complete